Patents by Inventor Ashok Anantanarayan

Ashok Anantanarayan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6579873
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I wherein R1, R2, Ar1 and HetAr2 are as described in the specification.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: June 17, 2003
    Assignee: Pharmacia Corporation
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6525059
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R 2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: February 25, 2003
    Assignee: G. D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6514977
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: February 4, 2003
    Assignee: G.D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xu, Ish K. Khanna, Yi Yu
  • Substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6423713
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: July 23, 2002
    Assignee: G. D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Paul W. Collins, Joyce Zuowu Crich, Rajesh Devraj, Daniel L. Flynn, Lifeng Geng, Matthew J. Graneto, Cathleen E. Hanau, Gunnar J. Hanson, Susan J. Hartmann, Michael Hepperle, He Huang, Francis J. Koszyk, Shuyuan Liao, Suzanne Metz, Richard A. Partis, Thao D. Perry, Shashidhar N. Rao, Shaun Raj Selness, Michael S. South, Michael A. Stealey, John Jeffrey Talley, Michael L. Vazquez, Richard M. Weier, Xiangdong Xi, Ish K. Khanna, Yi Yu
  • 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Publication number: 20020086869
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.
    Type: Application
    Filed: December 18, 2001
    Publication date: July 4, 2002
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Patent number: 6335336
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: January 1, 2002
    Assignee: G.D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • Substituted pyrazoles suitable as p38 kinase inhibitors
    Patent number: 6087496
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I: ##STR1## wherein R.sup.1, R.sup.2, Ar.sup.1 and HetAr.sup.2 are as described in the specification.
    Type: Grant
    Filed: April 1, 1999
    Date of Patent: July 11, 2000
    Assignee: G. D. Searle & Co.
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier
  • 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
    Patent number: 5932576
    Abstract: A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: August 3, 1999
    Assignee: G. D. Searle & Company
    Inventors: Ashok Anantanarayan, Michael Clare, Lifeng Geng, Gunnar J. Hanson, Richard A. Partis, Michael A. Stealey, Richard M. Weier